← Eichor
Study identifier: NCT06118788 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Condition: Leukemia, Myeloid, Acute  ·  Sponsor: Guangzhou Bio-gene Technology Co., Ltd

PhasePhase 1/Phase 2
Planned participants24
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This is a single-arm, single-dose dose-escalation and dose-expansion study.

This description comes directly from the study's public registry record.

Talk to the study team

Min Luo, Doctorate  ·  +86 020 32030437  ·  mluo@gzbiogene.com

Always discuss trial participation with your own doctor first.

Locations (3)

ZhuJiang Hospital of Southern Medical UniversityGuangzhou, Guangdong, ChinaRecruiting
Nanfang Hospital of Southern Medical UniversityGuangzhou, Guangdong, ChinaRecruiting
The First Affiliated Hospital, Zhejiang University School of MedicineHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06118788